Addiction medicine AI scribe 2026: ASAM Criteria, MAT buprenorphine, 42 CFR Part 2, PMP audit, and the post-MAT-Act surge

May 9, 2026 · 7 min read

Outpatient addiction medicine in 2026 is the fastest-growing primary-care-adjacent specialty in the United States. The MAT Act (passed late 2022, effective 2023) eliminated the X-waiver requirement for buprenorphine prescribing, opening the door for any DEA-registered clinician to prescribe MAT for opioid use disorder. Three years later, the practical effect is a wave of family medicine, internal medicine, psychiatry, and emergency medicine clinicians integrating SUD treatment into their practices, plus a parallel expansion of addiction medicine fellowship-trained physicians running dedicated outpatient clinics.

The documentation requirements are some of the heaviest in outpatient medicine: ASAM Criteria placement reasoning, structured biopsychosocial assessment, MAT induction and maintenance details, controlled-substance prescribing audit fields, 42 CFR Part 2 confidentiality handling, DEA + state PMP review documentation, and SUD-specific Z-code SDoH capture. Generic ambient scribes do not surface any of this; an addiction-medicine-tuned schema does.

The 2026 addiction-medicine-aware AI scribe stack handles five things general scribes do poorly: ASAM-aligned biopsychosocial documentation, MAT induction and maintenance audit fields, 42 CFR Part 2 release-protection language, DEA + state PMP review capture, and the SDoH Z-codes that drive value-based SUD payment models.

Visit-type adaptation

Outpatient addiction medicine has four core visit types:

• Initial SUD evaluation — comprehensive biopsychosocial across substance, mental health, medical, social. ASAM Criteria placement reasoning. 60-90 min. Often coded H0001 (in SUD treatment programs) or 99204/99205 (medical office).
• MAT induction — buprenorphine first dose under observation, COWS scoring, dose titration plan. State and program protocols vary.
• MAT maintenance follow-up — counseling content, UDS results, PMP review, treatment agreement adherence, dose adjustments. Often weekly, biweekly, or monthly depending on stability.
• Concurrent psychotherapy — CBT for SUD, MI, contingency management, group therapy attendance.

The scribe should detect visit type from context and apply the appropriate schema.

The addiction medicine system prompt

You are documenting an outpatient addiction medicine encounter.

INPUT:
- Encounter audio transcript
- Patient profile: prior SUD diagnoses, current MAT regimen, psych comorbidities,
  medical comorbidities (HCV, HIV, liver), prior treatment episodes
- Recent UDS results
- State PMP / PDMP recent fills (controlled substances)
- Treatment agreement status
- ASAM Criteria current placement (Level 1 outpatient, 2.1 IOP, 2.5 PHP, etc.)

DETERMINE visit type, then apply schema:

For initial SUD evaluation:
1. Substance use history (each substance: route, frequency, last use, longest sobriety)
2. Withdrawal history and current symptoms (CIWA / COWS / CINA as applicable)
3. Treatment history (detox, residential, IOP, MAT, AA/NA, prior providers)
4. Medical comorbidities (HCV, HIV, liver function, endocarditis history, abscesses)
5. Psychiatric comorbidities (depression, PTSD, anxiety, bipolar, ADHD)
6. Social: housing, employment, legal, family, social support
7. Trauma history (only what patient volunteered; do not infer)
8. Mental status exam
9. Risk assessment: overdose risk, suicide risk (C-SSRS), violence
10. ASAM Criteria placement: dimensional assessment (intoxication/withdrawal,
    biomedical, emotional/behavioral/cognitive, readiness, relapse risk, recovery
    environment) and recommended LOC with reasoning
11. Treatment plan: MAT eligibility, counseling modality, frequency, lab plan,
    safety plan if indicated, harm reduction (naloxone, fentanyl test strips, sterile
    syringes per state law)

For MAT induction:
1. Confirm OUD diagnosis (DSM-5-TR criteria met) and indication
2. COWS score at baseline
3. Last opioid use timing and verification (UDS)
4. Buprenorphine first dose: amount, observation period, COWS at 30/60/120 min
5. Adverse effects monitored
6. Dose titration plan and follow-up timing
7. Naloxone prescribed
8. Treatment agreement signed
9. PMP review documented

For MAT maintenance follow-up:
1. Interval substance use (self-report + UDS)
2. Cravings, withdrawal symptoms, side effects
3. Medication adherence and pickup pattern
4. Counseling/therapy attendance
5. Recovery support engagement (AA/NA, peer support, sponsor)
6. Mental health status (brief MSE)
7. Medical follow-up (HCV, HIV, liver, vaccinations, contraception)
8. Plan: dose continuation/adjustment, UDS schedule, PMP next review,
   refills (specify days supply per state rules)

CONTROLLED SUBSTANCE AUDIT (every visit involving CS):
- Medical necessity rationale
- PMP / PDMP review date and findings
- Treatment agreement status
- Pill count or UDS if applicable
- Dose justification
- Refill quantity and prescription notes

42 CFR PART 2 (default for SUD treatment program records):
- Flag note as Part 2 protected
- Confirm consent on file for any disclosure
- Use "without prior written consent" language for release
- Defer release decisions to clinician

SDOH Z-CODES surfaced when present:
- Z59.0 Homelessness
- Z59.1 Inadequate housing
- Z63.0 Family discord
- Z65.4 Victim of crime / abuse
- Z60.2 Living alone
- Z56.x Employment problems

Cite transcript. Use clinically defensible language; preserve quotes that affect
risk or capacity determination.

ASAM Criteria as the placement language

The American Society of Addiction Medicine Criteria is the de facto standard for substance use treatment placement. Six dimensions (acute intoxication / withdrawal, biomedical conditions, emotional / behavioral / cognitive, readiness to change, relapse / continued-use potential, recovery environment) inform a recommended level of care (Level 0.5 early intervention through Level 4 medically managed inpatient). Payors increasingly require ASAM-aligned placement reasoning for prior authorization. A scribe that produces dimension-by-dimension reasoning text, with an explicit LOC recommendation, makes auth submission and audit defense routine.

MAT and the post-MAT-Act prescribing surge

Buprenorphine prescribing for OUD no longer requires the DATA-2000 X-waiver (eliminated by the MAT Act, effective 2023). Any DEA-registered clinician can prescribe within their normal scope. Practical implications for documentation: induction protocols still vary by state Medicaid and individual prescribers, but the audit trail (medical necessity, OUD criteria met, naloxone co-prescribed, treatment agreement, UDS schedule, PMP review) remains the same and is what insurers and DEA inspections look for. Methadone for OUD remains restricted to OTPs (opioid treatment programs); buprenorphine maintenance can be done in any office setting with appropriate counseling support.

42 CFR Part 2 and the 2024 Final Rule

SUD treatment records from federally assisted programs receive heightened confidentiality under 42 CFR Part 2. The 2024 Final Rule (effective 2026) aligned aspects with HIPAA — allowing single-consent for treatment, payment, and operations — but kept the consent requirement and prohibition on use in legal proceedings without specific patient authorization or court order. Any chart with SUD treatment content from a Part 2-covered source should be flagged for Part 2 handling at the documentation layer rather than relying on downstream filtering.

The volume economics

An outpatient addiction medicine practitioner running a buprenorphine maintenance panel of 100-200 patients with weekly-to-monthly visits, plus 5-10 new evaluations per week, generates 25-40 visits per day at peak. Most are 15-20 minute follow-ups, with longer slots for evaluations. Per-minute documentation cost for a busy day: 22 hours of patient audio × $0.05 = ~$66/day with the LessRec DIY stack, vs $200-300/month subscription floor. The variable structure is more important than the absolute dollar — addiction-medicine practices have variable panels (member churn, missed appointments, incarceration absences, residential placements) and the no-floor pricing absorbs the variance.

Vendor and DIY paths

Vendor scribes capture the conversation. They underdeliver on ASAM dimensional reasoning, COWS / CIWA scoring placement, 42 CFR Part 2 flagging, PMP audit fields, and SDoH Z-code surfacing. The DIY stack — LessRec Whisper API + an addiction-medicine-tuned system prompt + your EHR's structured fields — produces audit-defensible documentation across SAMHSA, DEA, state Medicaid, and commercial-payor reviews.

BAA chain

Practice + EHR (NextGen Behavioral Health, Valant, addiction-specific platforms like ZenCharts, Sigmund AURA, Methasoft) + transcription vendor + LLM vendor. Part 2-covered records require explicit consent for any disclosure outside the chain.

When to start

Outpatient addiction medicine prescribers should not adopt a generic scribe. The audit trail is unforgiving: DEA, SAMHSA, state Medicaid, commercial payors, and accreditation bodies (CARF, JCAHO) all scrutinize SUD documentation. The DIY stack with an ASAM-tuned, Part 2-aware schema is the path that delivers defensible documentation at the variable cost the practice actually runs at.